Lyterian Therapeutics
Katherine Reiter has over 14 years of work experience in scientific research. Katherine has most recently worked at Lyterian Therapeutics as a Senior Scientist since February 2023. Prior to that, they were a Research Scientist I at the Broad Institute of MIT and Harvard from November 2021 to February 2023. Katherine also served as a Postdoctoral Fellow at the University of Washington from January 2016 to November 2021. Katherine began their career as a Graduate Student at the Johns Hopkins Bloomberg School of Public Health, where they focused on characterizing the SUMO conjugation machinery in the malaria parasite and published several papers and a methods chapter. Katherine also gained research experience as an Undergraduate Researcher at Emory University.
Katherine Reiter obtained their Bachelor of Science (B.S.) degree in Biology, General and their Bachelor of Arts (B.A.) degree in Chemistry from Emory University, where they studied from 2005 to 2009. Katherine then went on to pursue their Doctor of Philosophy (PhD) in Biochemistry and Molecular Biology at Johns Hopkins Bloomberg School of Public Health, completing their studies in 2015.
This person is not in any offices
Lyterian Therapeutics
1 followers
Lyterian Therapeutics derives its name from the Greek word λυτήριος or lutḗrios, that defines the termination, healing, or end of disease. Disease resolution is coordinated by endogenous and exogenous agents that recruit cells and other effectors to the site of injury. We are inspired to learn from the logic that orchestrates homeostatic equilibria and fosters healing in response to disease. At Lyterian Therapeutics, we are committed to developing medicines for patients in need by co-opting physiologically relevant protein homeostatic mechanisms to regulate genetically validated targets.
Employees
1-10